News Highlights

Check this page for recent news from Appili Therapeutics.

Members of the media can contact us here, or for general inquiries, contact us here.

September 23, 2021
Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus™ for the Treatment of Mild-to-Moderate COVID-19
September 20, 2021
Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™ for COVID-19 Patients
September 17, 2021
Appili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus™ Viral Shedding Sub-Study for Mild-to-Moderate COVID-19 Patients
September 8, 2021
Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders
August 18, 2021
Appili Therapeutics Announces Closing of $3.5 Million Funding Agreement